ArticleMicrobiology spectrum2026
Development of recombinant fowl adenovirus serotype 4 harboring the HiBiT-Tag reporter and its utility in antiviral research.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe hydropericardium-hepatitis syndrome (HHS) caused by fowl adenovirus 4 (FAdV-4) significantly affects the global poultry industry. However, there is currently no convenient and sensitive platform available for the rapid screening of antiviral drugs and the detection of neutralizing antibodies. Here, we first established an improved reverse genetics system for FAdV-4 Y17215-1 strain and identified the optimal insertion site for expressing foreign genes (between the ORF19A and ORF4 genes). To obtain a quantifiable recombinant reporter FAdV-4, the HiBiT-tag reporter gene was inserted into this site, and recombinant FAdV-4 expressing the HiBiT gene (rFAdV-4-HiBiT) was successfully rescued. Further analysis showed that rFAdV-4-HiBiT had similar growth kinetics to the parental virus and retained luciferase activity and genetic stability after 10 rounds of serial passages. A proof-of-concept test confirmed that rFAdV-4-HiBiT can be used to rapidly quantify anti-FAdV-4 neutralizing antibodies in chicken serum samples and screen for antiviral agents, including antiviral drugs and proteins, based on the intensity of luciferase activity. Collectively, the HiBiT-tagged virus rFAdV-4-HiBiT provides a robust tool for the rapid detection of FAdV-4 and facilitates the development of novel therapeutics and vaccines for FAdV-4. IMPORTANCE: The epidemic spread of fowl adenovirus 4 (FAdV-4) presents significant challenges for the global poultry industry. However, there are currently few convenient and sensitive platforms available for antiviral drug screening and neutralizing antibody detection. In this study, we first established an improved reverse genetics system for the FAdV-4 and screened for the optimal insertion site for foreign genes between ORF19A and ORF4. Furthermore, the HiBiT gene was further inserted into this site, and rFAdV-4-HiBiT was successfully rescued. A luciferase-based FAdV-4 neutralizing antibody detection method has been successfully established, which can reduce detection time and greatly enhance the efficiency of neutralizing antibody testing. Furthermore, this system can serve as a more convenient screening platform for anti-FAdV-4 drugs. Collectively, rFAdV-4-HibiT represents an important tool with great potential for facilitating the development of novel therapeutics and vaccines for FAdV-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.